Shots:
- Aligos has entered into an exclusive license agreement with Xiamen Amoytop Biotech, granting Amoytop rights to develop & commercialize pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection
- As per the deal, Aligos will receive an $25M upfront & ~$420M in clinical, regulatory, & sales milestones along with tiered, high single-digit royalties, while retaining rights in the US, EU, South Korea, Japan, & all other markets. Also, Aligos will retain the right to conduct clinical trials in Greater China
- Pevifoscorvir sodium is being evaluated in the P-IIB (SUPREME) trial against tenofovir disoproxil fumarate, with the second interim analysis expected in the H2’26 & topline data planned for 2027
Ref: Globenewswire | Image: Aligos Therapeutics & Amoytop Biotech |Press Release
Related News: Eli Lilly to Acquire CrossBridge Bio for ~$300M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
